BioMarin's Vimizim gets European approval

The European Commission approved Vimizim elosulfase alfa from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to treat mucopolysaccharidosis IVA (MPS-IVA, Morquio's syndrome), a rare inherited lysosomal storage disease. The company said it is working with individual countries to establish Vimizim's price and will begin supplying the drug in the EU on Wednesday. BioMarin launched the recombinant human N-acetylgalactosamine-6-sulfatase in the U.S. in February. The company said it still expects 2014 Vimizim sales of $60-$70 million (see BioCentury Extra, Feb. 18). ...